Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma (NCT03372837) | SymBio Pharmaceuticals | 2018-01-15 |
Track Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL automatically
Every clearance here is in the API, with alerts when new ones post.